IRIS
CONSOLARO, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 15.377
AS - Asia 40
SA - Sud America 13
Totale 15.430
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 15.375
CN - Cina 32
BR - Brasile 11
VN - Vietnam 7
AR - Argentina 1
CO - Colombia 1
NL - Olanda 1
RU - Federazione Russa 1
SG - Singapore 1
Totale 15.430
Salva come PNG Salva come JPEG
Città #
Genova 8.887
Genoa 3.789
Rapallo 1.366
Vado Ligure 1.299
Bordighera 31
Beijing 14
Hanoi 4
Ho Chi Minh City 2
Anápolis 1
Bertioga 1
Candeias 1
Cedro 1
Cruzeiro 1
Dores de Guanhães 1
Juiz de Fora 1
Pereira 1
Porto Alegre 1
Punta Alta 1
Santo André 1
Singapore 1
São Lourenço 1
Thái Nguyên 1
Uberlândia 1
Totale 15.407
Salva come PNG Salva come JPEG
Nome #
Juvenile Idiopathic Arthritis: Diagnosis and Treatment 189
A Meta-Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis 185
MRI versus conventional measures of disease activity and structural damage in evaluating treatment efficacy in juvenile idiopathic arthritis. 174
Parent and child acceptable symptom state in juvenile idiopathic arthritis. 173
The Slovak version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 166
The Slovene version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 165
The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 161
Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis 158
Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score 157
Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology 157
Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial 155
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept 152
Advances in biomarkers for paediatric rheumatic diseases 151
The Croatian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 150
A New Approach to Clinical Care of Juvenile Idiopathic Arthritis: The Juvenile Arthritis Multidimensional Assessment Report 149
IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis 149
Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis 149
Current Research in Outcome Measures for Pediatric Rheumatic and Autoinflammatory Diseases 148
Development and initial validation of composite parent and child centered disease assessment indices for juvenile idiopathic arthritis. 145
Clinical outcome measures in juvenile idiopathic arthritis 144
Development and testing of a hybrid measure of muscle strength in juvenile dermatomyositis for use in routine care 142
Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with juvenile idiopathic arthritis 141
Evaluation of 21-Numbered Circle and 10-Centimeter Horizontal Line Visual Analog Scales for Physician and Parent Subjective Ratings in Juvenile Idiopathic Arthritis 140
An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis 138
Seeking insights into the EPidemiology, treatment and Outcome of Childhood Arthritis through a multinational collaborative effort: Introduction of the EPOCA study. 138
Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept. 135
The Algerian Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 134
A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis 134
The Bulgarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 133
Recent therapeutic advances in juvenile idiopathic arthritis 133
Development and testing of reduced joint counts in juvenile idiopathic arthritis. 132
The Chilean Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 132
Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries 132
The Flemish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 131
Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis 131
Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016 131
Defining criteria for disease activity States in nonsystemic juvenile idiopathic arthritis based on a three-variable juvenile arthritis disease activity score. 130
Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. 130
A child with a novel ACAN missense variant mimicking a septic arthritis 130
Development and validation of a composite disease activity score for juvenile idiopathic arthritis 129
The Colombian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 129
The Turkish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 129
TCR repertoire sequencing identifies synovial Treg cell clonotypes in the bloodstream during active inflammation in human arthritis 128
The Swedish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 128
The Finnish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 128
The Russian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 128
Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study 128
Disease activity and damage in juvenile idiopathic arthritis: Methotrexate era versus biologic era 126
Filling the Gap: Toward a Disease Activity Tool for Systemic Juvenile Idiopathic Arthritis 125
The British English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 125
It is worth including assessment of disease activity state in juvenile arthritis clinical trials. 124
The Canadian English and French versions of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 124
Unraveling the phenotypic variability of juvenile idiopathic arthritis across races or geographic areas - Key to understanding etiology and genetic factors? 123
The Serbian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 123
The Mexican Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 123
The Ecuadorian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 123
The Hindi version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 123
The Ukrainian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 122
The Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 122
Predictors of effectiveness of anakinra in systemic juvenile idiopathic arthritis 122
The Afrikaans version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 121
The Georgian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 120
Glucocorticoids in juvenile idiopathic arthritis. 119
The Lithuanian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 119
The Swiss French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 119
Paediatric rheumatology: Juvenile idiopathic arthritis--are biologic agents effective for pain? 118
Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop 118
The Hebrew version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 117
The Dutch version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 117
The Latvian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 117
Female sex and oligoarthritis category are not risk factors for uveitis in Italian children with juvenile idiopathic arthritis. 116
Prevalence of overweight and obesity in 2- to 6-year-old Italian children 115
The Farsi version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 115
The Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 115
The Thai version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 115
The Castilian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 115
Delineating the role of multiple intraarticular corticosteroid injections in the management of juvenile idiopathic arthritis in the biologic era. 114
The Paraguayan Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 114
Defining criteria for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score. 114
The Czech version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 114
Defining criteria for disease activity states in juvenile idiopathic arthritis 113
The Argentinian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 113
The Estonian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 113
The Norwegian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 113
The Danish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 110
The Omani Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 110
The American English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 109
Measures of disease activity and damage in pediatric systemic lupus erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Physician's Global Assessment of Disease Activity (MD Global), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI; SDI). 108
Ghrelin, insulin sensitivity and postprandial glucose disposal in overweight and obese children 108
The Brazilian Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 108
The French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 106
The Hungarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 105
Determinants of discordance between criteria for inactive disease and low disease activity in juvenile idiopathic arhritis 105
The Polish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 103
The Greek version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 101
Information technology in paediatric rheumatology 100
The Libyan Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 100
Analysis of arthritis flares after achievement of inactive disease with methotrexate monotherapy in juvenile idiopathic arthritis 98
Optimisation of disease assessments in juvenile idiopathic arthritis. 96
Critical role of STIR MRI in early detection of post-streptococcal periostitis with dysproteinaemia (Goldbloom's syndrome) 96
Totale 12.803
Salva come PNG Salva come JPEG
Categoria #
all - tutte 56.914
article - articoli 56.914
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 113.828
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.093 0 0 0 150 76 70 137 135 71 178 70 206
2021/20221.488 72 59 122 119 55 123 61 326 125 175 63 188
2022/20231.632 147 147 21 144 251 274 9 159 276 14 165 25
2023/2024822 35 113 35 110 71 73 89 46 41 35 48 126
2024/20252.973 78 217 111 208 422 365 297 469 75 139 240 352
2025/20261.161 577 161 216 207 0 0 0 0 0 0 0 0
Totale 15.945